ClinicalTrials.gg
RecruitingNCT06786000tDCS and mCIMTUpdated Jan 22, 2025

Neurophysiological and Behavioral Effects of Combining Transcranial Direct Current Stimulation (tDCS) and Modified-Constraint Induced Movement Therapy (mCIMT)

An interventional study of Anodal tDCS combined with mCIMT and Cathodal tDCS combined with mCIMT in Stroke, Hemiparesis of the Upper Limb Following Stroke and Stroke Rehabilitatiom, sponsored by King Saud University. Recruiting at 1 site in Saudi Arabia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-22.

Sponsored by King Saud University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 8 months after the study started (first participant enrolled Apr 2023, registered Jan 2025).
  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Stroke with a site in Saudi Arabia — 10 open to participants now, 11 under way, 1 of them phase 3. Stroke · Saudi Arabia.

Planned enrollment
3rd of 27
300 · median 40
Started
2023
with 4 others
No phase
25 of 30
9 open now
Primary completion
2025-04
later than 1 of 10 live
Registered
23rd of 30
by date
Lead sponsor
9 of 30
King Saud University

Among the 30 studies in Stroke with a site in Saudi Arabia, this one is the 3rd largest by planned enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2023, is one of 25 with no phase, reaches primary completion later than 1 of the 10 other live ones, and was the 23rd registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

10 of the 30 studies in Stroke with a site in Saudi Arabia are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Saudi Arabia have not opened yet or have stopped. Only those recruiting at a site in Saudi Arabia →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Stroke with a site in Saudi Arabia, or all of them as a file.
02

Study summary

This clinical trial aims to evaluate the effect of different types of tDCS modulation with mCIMT in improving affected upper-limb motor function for stroke patients. The main question it seeks to answer:

Which type of tDCS (bi-hemispheric, anodal, or cathodal) combined with the mCIMT program leads to greater improvement in affected upper-limb function in patients with stroke? Researchers will compare these three types of tDCS to a sham tDCS. To see which kind of tDCS protocol combined with the mCIMT program will be more effective in improving affected upper-limb function for stroke patients.

Participants will:

  1. Participants will receive 12 sessions of mCIMT combined with tDCS or mCIMT alone.
  2. Visit the clinic three times a week for four weeks.
  3. Participants will do fMRI and TMS before and after the program and three times of assessment before and after two weeks after the program.
Read the detailed description

Background: After a stroke, intense motor rehabilitation is required to facilitate motor recovery. In specific, combining tDCS with neurorehabilitation interventions boosts the responses of the brain to the interventions and maximizes the effects of rehabilitation to improve upper limb recovery post-stroke. Objectives: To evaluate the effect of different modes of tDCS modulation with mCIMT in improving affected upper-limb motor recovery for patients with stroke. Method: a randomizing control trial design, after performing a baseline assessment, the participants will be randomly assigned to one of the four groups: the anodal tDCS +mCIMT group, the cathodal tDCS +mCIMT group, the bihemispheric tDCS +mCIMT group, and the mCIMT alone group. Inclusion Criteria, adult participants clinically diagnosed and confirmed by imaging of ischemic or hemorrhagic cerebrovascular accident, participant's age older than 18 years, Stroke onset more than 3 months with unilateral motor deficits, Adequate cognitive function is required to follow instructions. The Arabic version of the Mini-Mental State Examination (MMSE) should be ≥24, 10° of active extension to the metacarpophalangeal and interphalangeal joints and 20° at the wrist, and not participating in other clinical, or research studies at the same time. Exclusion Criteria, Severe muscle spasticity at the affected limb at all joints (the Modified Ashworth Scale scores > 3), Contraindications to NIBS, unilateral neglect, Other neurologic or orthopedic conditions that may affect hand function, and unstable medical conditions. The total intervention period will be performed 3 times a week for 4 weeks. Each participant will undergo motor impairment and physiological assessments at baseline, during and after the intervention. Functional outcome measures: Fugl-Meyer Assessment Scale - upper extremity (FMA-UE), Wolf Motor Function Test (WMFT), Nine-Hole Peg Test (NHPT), Arabic version of Stroke Impact Scale (SIS-16), and Stroke-Specific Measure of Adherence to Home-based Exercises (SS-MAHE). Physiological outcome measures: Cortical Excitability Assessment will be measured by Transcranial Magnetic Stimulation (TMS) with electromyographic (EMG) and functional magnetic resonance imaging (fMRI).

03

Conditions studied

  • Stroke
  • Hemiparesis of the Upper Limb Following Stroke
  • Stroke Rehabilitatiom

Keywords

  • stroke
  • ischemic stroke
  • hemorrhagic stroke
  • tDCS
  • mCIMT
  • hemiparesis
  • neural activation
  • primary motor cortex
  • NIBS
  • non invasive brain stimulation
  • trans direct current stimulation
  • modified constraint induced movement therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult participants clinically diagnosed and confirmed by imaging of ischemic or hemorrhagic cerebrovascular accident (Dahl et al., 2008; Jin et al., 2019).
  2. Participant's age older than 18 years (Baltar et al., 2020).
  3. Stroke onset more than 3 months with unilateral motor deficits (Lin et al., 2010).
  4. Adequate cognitive function is required to follow instructions. The Arabic version of the (MMSE) should be ≥24 (Kim, 2021).
  5. 10° of active extension to the metacarpophalangeal and interphalangeal joints and 20° at wrist will be assessed by manual goniometer (Dahl et al., 2008).
  6. Fugl-Meyer assessment (FMA) scores between 19 and 58, indicating moderate to mild impairments.
  7. Not participating in other clinical, or research studies at the same time.

Exclusion criteria

Exclusion Criteria:

  1. Severe muscle spasticity at the affected limb at all joints (the Modified Ashworth Scale scores > 3) (Baltar et al., 2020).
  2. to NIBS (Bornheim et al., 2019).
  3. Unilateral neglect (Dahl et al., 2008)
  4. Other neurologic or orthopedic conditions that may affect hand function.
  5. Unstable medical conditions.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Anodal tDCS combined with mCIMT

    20 minutes of anodal tDCS followed by 1 hour of the mCIMT program

    Device: Anodal tDCS combined with mCIMT

  • Experimental
    Cathodal tDCS combined with mCIMT

    20 minutes of cathodal tDCS followed by 1 hour of the mCIMT program

    Device: Cathodal tDCS combined with mCIMT

  • Experimental
    Bihemispheric tDCS combined with mCIMT

    20 minutes of bihemispheric tDCS followed by 1 hour of the mCIMT program

    Device: Bihemispheric tDCS combined with mCIMT

  • Sham comparator
    Sham tDCS combined with mCIMT

    20 minutes of anodal tDCS (after 30 seconds of stimulation, the stimulator will switch off) followed by 1 hour of the mCIMT program

    Device: Sham tDCS combined with mCIMT

Interventions

  • DeviceAnodal tDCS combined with mCIMT

    20 minutes of anodal tDCS followed by 1 hour of the mCIMT program. The anodal electrode will be placed over the ipsilesional M1 (primary motor cortex, C3 or C4 according to EEG 10/20 system), and the cathodal electrode over the contralateral supraorbital area (Fp1 or Fp2) ). Leading to subthreshold depolarization to promote cortical excitation. And twelve different oriented tasks will be used during the 1-hour training period.

  • DeviceCathodal tDCS combined with mCIMT

    20 minutes of cathodal tDCS followed by 1 hour of the mCIMT program. the cathodal electrode will be placed over the contralesional M1, and the anodal electrode over the contralateral supraorbital area (Fp1 or Fp2). leading to subthreshold polarization to promote cortical inhibition. And twelve different oriented tasks will be used during the 1-hour training period.

  • DeviceBihemispheric tDCS combined with mCIMT

    20 minutes of Bihemispheric tDCS followed by 1 hour of the mCIMT program. the cathodal electrode will be placed over the primary motor cortex (M1) of the contralesional hemisphere and the anodal electrode will be placed above the ipsilateral M1 position (C3 or C4 positions, according to the 10/20 EEG system). And twelve different oriented tasks will be used during the 1-hour training period.

  • DeviceSham tDCS combined with mCIMT

    20 minutes of sham tDCS followed by 1 hour of the mCIMT program. the same stimulation place and parameters will be used as in the anodal group. However, after 30 seconds of stimulation, the stimulator will switch off. This provides the participants with the experience of the initial itchy sensation that occurs during tDCS, which is required for efficient masking. And twelve different oriented tasks will be used during the 1-hour training period.

06

What researchers measure

Primary outcomes

  1. Fugl-Meyer Assessment Scale - upper extremity (FMA-UE)

    The upper extremity domain of FMA consists of 33 items (reflex activity, volitional movement within synergies, volitional movement mixing synergies, volitional movement with little or no synergy, wrist, hand, coordination/ speed). On a 3-point ordinal scale, 0 = cannot perform, 1 = performs partially, and 2 = performs fully. The upper extremity domain has a total score of 66. A higher score indicated better performance of the affected side.

    Time frame: at baseline, and after 2 weeks, and after intervention (4 weeks).

  2. Wolf Motor Function Test (WMFT)

    It is used to assess upper-limb performance through timed and functional tasks (Wolf et al., 2001). The WMFT is preferred to frequently used upper limb performance tests since it assesses a wide range of functional activities (from simple to complex) and investigates both performance time and movement quality (Morris et al., 2001). The modified WMFT consists of 17 items, 2 of which are strength measurements, and the remaining 15 items are functional tasks that gradually progress from simple movements in the proximal joint to complex movements in the distal joint. Each of the 15 tasks is timed to completion, up to a maximum of 120 seconds (Wolf et al., 2001). The items are scored on a 6-point scale ranging from 0 (does not attempt with the upper limb being tested) to 5 (uses the limb being tested, movement appears normal) (Wolf et al., 2005). A lower score indicates a lower functional level (Wolf et al., 2005).

    Time frame: at baseline, and after 2 weeks, and after intervention ( 4 weeks).

  3. Nine-Hole Peg Test (NHPT)

    The Nine-Hole Peg Test (NHPT) is one of the most commonly used performance tests for measuring hand function and manual dexterity in stroke patients (Chen et al., 2009; Mathiowetz et al., 1985). The NHPT consists of a container with nine pegs and a pegboard with nine holes. The board will be placed at the midline of the patient, with the container containing the pegs on the side of the hand being evaluated. The NHPT requires the patient to pick up the pegs from the container with the affected upper limb, transfer and insert them into the holes of the pegboard until it is full, and then return them to the container. Patients will be instructed to complete the test as quickly and accurately as possible (Sommerfeld et al., 2004). The score will be based on the time it takes to complete the test activity, which will be recorded in seconds. The stopwatch should be started when the patient touches the first peg until the last peg is put in the container (Oxford Grice et al., 2003).

    Time frame: at baseline, and after 2 weeks, and after intervention ( 4 weeks).

  4. Cortical Excitability Assessment

    The Transcranial Magnetic Stimulation (TMS) will be used to assess the corticospinal excitability through the measurement of the TMS-elicited motor evoked potential (MEP) in both the lesioned and the nonlesioned motor cortices (Wassermann et al., 2008). Online monitoring of the electromyographic (EMG) activity in response to TMS will be performed, MEPs will be recorded from the left and the right first interosseous (FDI) muscles

    Time frame: at baseline and after intervention ( 4 weeks).

  5. Functional magnetic resonance imaging (fMRI)

    Functional magnetic resonance imaging (fMRI) is a type of magnetic resonance imaging (MRI) that measures brain activity and connectivity. During an fMRI scan, a block design will be used. Each scan will take 6 minutes and be split into six blocks in the following order, with a rest of 30 seconds between each of the 15 contractions that last 2 seconds each and 30 seconds of rest in between (Wen et al., 2014). In each task, participants will be asked to grip a rubber ball at a target pressure of 30% of their maximum voluntary contraction using their affected hand (Cheng et al., 2021; Ismail et al., 2014). Visual feedback will be provided for the patients to guide the movement (Könönen et al., 2012).

    Time frame: at baseline and after intervention ( 4 weeks).

  6. Wolf Motor Function Test (WMFT)

    It is used to assess upper-limb performance through timed and functional tasks (Wolf et al., 2001). The WMFT is preferred to frequently used upper limb performance tests since it assesses a wide range of functional activities (from simple to complex) and investigates both performance time and movement quality (Morris et al., 2001). The modified WMFT consists of 17 items, 2 of which are strength measurements, and the remaining 15 items are functional tasks that gradually progress from simple movements in the proximal joint to complex movements in the distal joint. Each of the 15 tasks is timed to completion, up to a maximum of 120 seconds (Wolf et al., 2001). The items are scored on a 6-point scale ranging from 0 (does not attempt with the upper limb being tested) to 5 (uses the limb being tested, movement appears normal) (Wolf et al., 2005). A lower score indicates a lower functional level (Wolf et al., 2005).

    Time frame: at baseline and after intervention ( 4 weeks).

Secondary outcomes

  1. Arabic version of Stroke Impact Scale (SIS-16)

    Stroke Impact Scale (SIS-16) is a stroke specific, self-reported outcome measure used to assess the impact of stroke on health-related quality of life status related to physical function (P. Duncan et al., 2003). It consists of 16 items, basic and instrumental activities of daily living (7 items), mobility (8 items), and hand function (1 item) on a 5-level Likert scale, 1 = inability to complete the item; 5 = not difficult at all (P. Duncan et al., 2003; P. W. Duncan et al., 2003). Higher scores indicate a better level of health-related quality of life status for stroke patients (P. W. Duncan et al., 2003).

    Time frame: at baseline, and after 2 weeks, and after intervention ( 4 weeks).

  2. Motor Activity log (MAL)

    The MAL consists of two scales; amount of use (AOU), which is the amount the stroke patient uses on the affected limb, and quality of movement (QOM), which is the patient's perceived quality of movement while performing 30 items of daily life (Taub et al., 1993). The items are scored on a 6-point scale ranging from 0 (did not use my weaker arm) to 5 (used my weaker arm as often as before the stroke) for measuring AOU; and to measure QOM, the patient is asked how well the affected limb helped during this activity. Possible scores range from 0 (my weaker arm was not used at all for that activity) to 5 (the ability to use my weaker arm for that activity was as good as before the stroke) (Taub et al., 1993).

    Time frame: at baseline, week 1, week 2, week 3 and after intervention ( 4 weeks).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Baltar A, Piscitelli D, Marques D, Shirahige L, Monte-Silva K. Baseline Motor Impairment Predicts Transcranial Direct Current Stimulation Combined with Physical Therapy-Induced Improvement in Individuals with Chronic Stroke. Neural Plast. 2020 Nov 25;2020:8859394. doi: 10.1155/2020/8859394. eCollection 2020. PubMed 33299400 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Apr 2025, 24 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 24 months is close to that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2025
First posted
Jan 22, 2025
StartActual
Apr 11, 2023
Primary completionEst.
Apr 11, 2025
CompletionEst.
Apr 11, 2025
Last update
Jan 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06786000
Collaborators
King Saud Medical City, King Fahad Medical City
Responsible party
Dr. Alaa Albishi (Associate Professor, King Saud University) — Principal investigator
First posted
Jan 22, 2025
Start date
Apr 11, 2023
Primary completion
Apr 11, 2025 (estimated)
Completion
Apr 11, 2025 (estimated)
Last update
Jan 22, 2025

Study contacts

Alaa M. Albishi, PhD in Rehabilitation Sciences
Contact
aalbeshi@KSU.EDU.SA
+966555090015
Ahmad O. Alokaily, PhD
Contact
aalokaily@ksu.edu.sa
+966557447442

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion